Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor

Ren Fail. 2021 Dec;43(1):886-889. doi: 10.1080/0886022X.2021.1930049.

Authors

Gang Wang¹, Ning Zhuo², Ying Luo³, Jie Li³

Affiliations

¹ Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.
² Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
³ Department of Nephrology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.

No abstract available

Publication types

Case Reports
Letter
Video-Audio Media

MeSH terms

Antineoplastic Agents / adverse effects*
Gastrointestinal Stromal Tumors / drug therapy*
Glomerulosclerosis, Focal Segmental / chemically induced*
Humans
Imatinib Mesylate / adverse effects*
Kidney Function Tests
Male
Middle Aged
Nephrosis, Lipoid / chemically induced*

Substances

Antineoplastic Agents
Imatinib Mesylate